Prevalence of cardiovascular risk factors inmale and female patients with primary hyperparathyroidism

Journal of Endocrinological Investigation

Volumn 35, Issue 6, 2012, Pages 548-552

  Han, D ^a   Trooskin, S ^a   Wang, X ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular disease; Diabetes; Hyperlipidemia; Hyperparathyroidism; Obesity

Indexed keywords

CALCIUM;

ADULT; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GOITER; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARATHYROID ADENOMA; PREVALENCE; PRIMARY HYPERPARATHYROIDISM; RETROSPECTIVE STUDY; SEX DIFFERENCE; UNITED STATES;

CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERPARATHYROIDISM, PRIMARY; HYPERTENSION; MALE; MIDDLE AGED; NEW JERSEY; OBESITY; PARATHYROID NEOPLASMS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84863957060     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7861     Document Type: Article

References (32)

1. Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006, 1: 171-7. (Pubitemid 43023239)
2. Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med 2004, 350: 1746-51. (Pubitemid 38501143)
3. Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism: 10-year prospective study. Mayo Clin Proc 1981, 56: 473-8. (Pubitemid 11023590)
4. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999, 341: 1249-55. (Pubitemid 29489739)
5. Potts JT, Franklin JE, Aurbach GD, et al. Proceedings of the NIH consensus development conference on diagnosis and management of asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991, 6 (Suppl 2): S1-166.
6. Bilezikian JP, Potts JT, El-Hajj Fuleihan G, et al. Summary statement from a workshop on asymptomatic hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002, 87: 353-61.
7. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008, 93: 3462-70.
8. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 1988, 67: 1294-8. (Pubitemid 19012967)
9. Guo CY, Thomas WE, al-Dehaimi AW, Assiri AM, Eastell R. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 1996, 81: 3487-91. (Pubitemid 26339904)
10. Bolland MJ, Grey AB, Ames RW, Horne AM, Gamble GD, Reid IR. Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone 2006, 38: 317-21. (Pubitemid 43255425)
11. Siilin H, Rastad J, Ljunggren O, Lundgren E. Disturbances of calcium homeostasis consistent with mild primary hyperparathyroidism in premenopausal women and associated morbidity. J Clin Endocrinol Metab 2008, 93: 47-53.
12. Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primaryhyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab 2005, 90: 1525-30. (Pubitemid 40464014)
13. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone level is associated with body mass index. The 5th Tromsø study. Eur J Endocrinol 2004, 151: 167-72. (Pubitemid 39207010)
14. Ayturk S, Gursoy A, Bascil Tutuncu N, Ertugrul DT, Guvener Demirag N. Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2006, 91: 4260-3. (Pubitemid 44833396)
15. Shaw JT, Purdie DM, Neil HA, Levy JC, Turner RC. The relative risks of hyperglycaemia, obesity and dyslipidaemia in the relatives of patients with type II diabetes mellitus. Diabetologia 1999, 42: 24-7. (Pubitemid 29039732)
16. Procopio M, Magro G, Cesario F, et al. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 Diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002, 19: 958-61. (Pubitemid 35356924)
17. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A. Clinical presentation of primary hyperparathyroidism in Europe: nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002, 17 (Suppl 2): N68-74. (Pubitemid 35222315)
18. Cardenas MG, Vigil KJ, Talpos GB, Lee MW, Peterson E, Rao DS. Prevalence of type 2 Diabetes mellitus in patients with primary hyperparathyroidism. Endocr Pract 2008, 14: 69-75.
19. Wermers RA, Khosla S, Atkinson EJ, et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998, 104: 115-22. (Pubitemid 28117404)
20. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. www.OpenEpi.com, updated 2010/19/09, accessed 2011/04/02.
21. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88: 1174-8. (Pubitemid 36337773)
22. Marcus R. The role of estrogens and related compounds in the management of primary hyperparathyroidism. J Bone Miner Res 2002, 17 (Suppl 2): N146-9. (Pubitemid 35222327)
23. Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J Biol Chem 2007, 282: 3098-106.
24. Sukumar D, Partridge NC, Wang X, Shapses SA. The high serum monocyte chemoattractant protein-1 in obesity is influenced by high parathyroid hormone and not adiposity. J Clin Endocrinol Metab 2011, 96: 1852-8.
25. Khan AA, Bilezikian JP, Potts JT Jr; Guest Editors for the Third International Workshop on Asymptomatic Primary Hyperparathyroidism. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J Clin Endocrinol Metab 2009, 94: 333-4.
26. Xu KT, Borders TF. Gender, health, and physician visits among adults in the United States. A J Pub Health 2003, 93: 1076-9.
27. Adam MA, Untch BR, Danko ME, et al. Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. J Clin Endocrinol Metab 2010, 95: 4917-24.
28. Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007, 92: 1687-92. (Pubitemid 46997172)
29. Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007, 92: 3114-21. (Pubitemid 47236379)
30. Bollerslev J, Rosen T, Mollerup CL, et al SIPH Study Group. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94: 2255-61.
31. Vestergaard P, Mollerup CL, Frøkjaer VG, Christiansen P, Blichert- Toft M, Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 2003, 27: 216-22. (Pubitemid 36926340)
32. Vestergaard P, Mosekilde L. Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 2003, 327: 530-4.